Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥120.0bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥236.9bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥116.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥956m2024-04-01 → 2024-09-30Cons.Operating income
Operating income−¥1.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥1.3bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income−¥7.2bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.6bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥1.6bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax−¥1.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥821m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥7.6bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥821m2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥291.4bnat 2024-09-30Cons.Assets
Total assets¥290.8bnat 2024-03-31Cons.Assets
Total assets¥284.6bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥155.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥148.3bnat 2024-03-31Cons.Liabilities
Net assets / equity¥136.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥142.5bnat 2024-03-31Cons.Net assets
Net assets / equity¥150.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥47.0bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥39.9bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥47.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥39.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥37.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.6bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥9.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥16.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥10.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-14.472024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-132.772023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-322023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio46.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio49.0%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio52.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥2.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥76.7bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥76.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥205m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥2.9bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥31.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥29.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥2.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2024-04-01 → 2024-09-30¥14.5bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2024-04-01 → 2024-09-30¥14.4bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥9m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2024-04-01 → 2024-09-30¥879m
—segment totalrevenue2024-04-01 → 2024-09-30¥122.4bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥120.0bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥2.4bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.5bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥2.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥72.4bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥72.3bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥74m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥6.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥33.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-09-30¥564m
—segment totalrevenue2023-04-01 → 2023-09-30¥119.6bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥116.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 536
ItemContextValueUnit
Allowance for doubtful accounts caPrior1YearInstant-678000000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-940000000JPY
Current assetsPrior1YearInstant123220000000JPY
Current assetsCurrentQuarterInstant127387000000JPY
Buildings and structures netPrior1YearInstant28441000000JPY
Buildings and structures netCurrentQuarterInstant27229000000JPY
Machinery equipment and vehicles netPrior1YearInstant13338000000JPY
Machinery equipment and vehicles netCurrentQuarterInstant6481000000JPY
Tools furniture and fixtures netPrior1YearInstant16847000000JPY
Tools furniture and fixtures netCurrentQuarterInstant15511000000JPY
LandPrior1YearInstant10129000000JPY
LandCurrentQuarterInstant9901000000JPY
Other net ppePrior1YearInstant12644000000JPY
Other net ppeCurrentQuarterInstant18037000000JPY
Property plant and equipmentPrior1YearInstant81400000000JPY
Property plant and equipmentCurrentQuarterInstant77162000000JPY
GoodwillPrior1YearInstant7399000000JPY
GoodwillCurrentQuarterInstant6886000000JPY
Customer related intangible assets iaPrior1YearInstant1968000000JPY
Customer related intangible assets iaCurrentQuarterInstant1808000000JPY
SoftwarePrior1YearInstant17825000000JPY
SoftwareCurrentQuarterInstant16857000000JPY
Other iaPrior1YearInstant18638000000JPY
Other iaCurrentQuarterInstant19139000000JPY
Intangible assetsPrior1YearInstant45832000000JPY
Intangible assetsCurrentQuarterInstant44692000000JPY
Investment securitiesPrior1YearInstant6438000000JPY
Investment securitiesCurrentQuarterInstant5307000000JPY
Other ioaPrior1YearInstant34269000000JPY
Other ioaCurrentQuarterInstant36740000000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-411000000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-1000000JPY
Investments and other assetsPrior1YearInstant40297000000JPY
Investments and other assetsCurrentQuarterInstant42047000000JPY
Noncurrent assetsPrior1YearInstant167530000000JPY
Noncurrent assetsCurrentQuarterInstant163901000000JPY
Deferred assetsPrior1YearInstant99000000JPY
Deferred assetsCurrentQuarterInstant82000000JPY
AssetsPrior1YearInstant290849000000JPY
AssetsCurrentQuarterInstant291371000000JPY
Notes and accounts payable tradePrior1YearInstant19729000000JPY
Notes and accounts payable tradeCurrentQuarterInstant18514000000JPY
Electronically recorded obligations operating clPrior1YearInstant1091000000JPY
Electronically recorded obligations operating clCurrentQuarterInstant455000000JPY
Short term loans payablePrior1YearInstant-JPY
Short term loans payableCurrentQuarterInstant10000000000JPY
Current portion of bondsPrior1YearInstant10000000000JPY
Current portion of bondsCurrentQuarterInstant10000000000JPY
Accounts payable otherPrior1YearInstant16027000000JPY
Accounts payable otherCurrentQuarterInstant10175000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass